Related Experiment Video
Updated: Jun 11, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Epidermal Growth Factor Receptor Emerges as a Viable Target for Reducing Tumorigenicity of MDCK Cells
Di Yang1,2,3,4, Yuejiao Liao1,2,3, Lingwei Huang2,5
1College of Veterinary Medicine, Gansu Agricultural University, Lanzhou 730070, China.
Abstract:
The MDCK cell line is perceived as better than the embryos of hen eggs for the production of influenza vaccines, but the tumorigenicity of these cells is concerning. Epidermal growth factor receptor (EGFR) is likely to be a crucial target that contributes to the tumorigenicity of MDCK cells. In this study, EGFR-knockdown and EGFR-overexpression cell lines were established. EGFR's influence on cell growth, migration, clonogenic ability, and flu virus susceptibility was evaluated in vitro, and its role in cell tumorigenicity was examined in nude mice. GST pull-down coupled with mass spectrometry (MS) and bioinformatics analysis identified EGFR-interacting proteins. The expression levels of these proteins, as well as those of PI3K-AKT- and MAPK-ERK-signaling-pathway-related molecules, were confirmed at both gene and protein levels. The result indicates that EGFR overexpression can enhance cell proliferation, migration, and clonal formation; EGFR knockdown could effectively curtail tumorigenesis and amplify the titers of influenza viruses in MDCK cells. An analysis of the underlying mechanism identified a total of 21 interacting proteins implicated in tumor formation, and among these, AKT1, CDK4, GNB2, and MAPK8 were confirmed at both gene and protein levels. EGFR can activate key factors of the PI3K-AKT signaling pathway, AKT and PI3K, and promote their phosphorylation levels. Consequently, we concluded that EGFR interacts with GNB2, facilitating transmembrane signal transduction, activating the PI3K-AKT signaling cascade, controlling cell cycle alterations, stimulating cell proliferation, and promoting tumorigenesis.
Insights
Epidermal growth factor receptor (EGFR) drives tumorigenicity in MDCK cells used for influenza vaccines. Reducing EGFR inhibits tumor growth and increases vaccine yield, offering a safer alternative to traditional methods.
Area of Science:
- Biotechnology
- Cell Biology
- Virology
Background:
- MDCK cells are preferred for influenza vaccine production over hen eggs.
- Tumorigenicity of MDCK cells is a significant safety concern.
- Epidermal growth factor receptor (EGFR) is implicated in MDCK cell tumorigenicity.
Purpose of the Study:
- To investigate the role of EGFR in MDCK cell tumorigenicity and influenza virus susceptibility.
- To identify EGFR-interacting proteins and signaling pathways involved in tumorigenesis.
- To evaluate EGFR modulation as a strategy for improving vaccine production safety and efficiency.
Main Methods:
- Established EGFR-knockdown and EGFR-overexpression MDCK cell lines.
- Performed in vitro assays for cell growth, migration, and clonogenic ability.
- Conducted in vivo tumorigenicity studies in nude mice.
- Utilized GST pull-down, mass spectrometry, and bioinformatics to identify interacting proteins.
- Confirmed protein and gene expression of signaling pathway molecules.
Main Results:
- EGFR overexpression enhanced MDCK cell proliferation, migration, and clonal formation.
- EGFR knockdown significantly reduced tumorigenesis and increased influenza virus titers.
- Identified 21 EGFR-interacting proteins, confirming AKT1, CDK4, GNB2, and MAPK8.
- EGFR activates the PI3K-AKT signaling pathway, promoting cell proliferation and tumorigenesis.
Conclusions:
- EGFR plays a critical role in MDCK cell tumorigenesis and influences influenza virus susceptibility.
- Targeting EGFR can mitigate tumorigenicity and enhance influenza vaccine production.
- EGFR interacts with GNB2, activating the PI3K-AKT pathway, controlling cell cycle, and promoting proliferation.
More Related Videos
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Related Concept Videos
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...